SCHEMBL1147527

SCHEMBL1147527

NC1CCC(Nc2ccnc3cc(Cl)ccc23)CC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT5B Q4FZB7 2/20 0.78
KMT5C Q86Y97 2/20 0.78
NSD2 O96028 1/20 0.71
CYP2D6 P10635 2/20 0.67
CYP2C19 P33261 1/20 0.67
KMT2A Q03164 3/20 0.65
ALDH1A1 P00352 2/20 0.65
MEN1 O00255 2/20 0.65
KDM4E B2RXH2 1/20 0.65
CYP1A2 P05177 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
FERMT2 Q96AC1 3/20 0.52
MAPT P10636 4/20 0.51
TDP1 Q9NUW8 3/20 0.51
CCR1 P32246 1/20 0.51
GAA P10253 2/20 0.50
NR4A2 P43354 1/20 0.50
NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4811736 1.00 KMT5B (0.78) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL3708467 1.00 KMT5B (0.78) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL3706336 1.00 KMT5B (0.78) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL6872111 0.93 KMT5B (0.89) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7207215 0.93 KMT5B (0.89) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL6872121 0.93 KMT5B (0.89) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7834815 0.92 KMT5B (0.70) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7834817 0.92 KMT5B (0.70) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7834821 0.92 KMT5B (0.70) KMT5BKMT5CNSD2CYP2D6CYP2C19
SCHEMBL7206080 0.87 KMT5B (0.79) KMT5BKMT5CNSD2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121699880-A Pseudomonas aeruginosa phage and application thereof 西北大学 2026-03-20 CN disclosed
CN-117035218-A Method, device and system for providing group synchronization based on biomarker 希纽吉有限公司 2023-11-10 CN disclosed
US-20120122923-A1 DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES SANOFI-AVENTIS (FR) 2012-05-17 US disclosed
US-20120122923-A1 DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES SANOFI-AVENTIS (FR) 2012-05-17 US disclosed
US-20110045100-A1 Antimalarial Quinolines and Methods of Use Thereof GEORGETOWN UNIVERSITY (US) 2011-02-24 US disclosed
WO-2009148659-A2 ANTIMALARIAL QUINOLINES AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2009-12-10 WO disclosed
WO-2009148659-A2 ANTIMALARIAL QUINOLINES AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2009-12-10 WO disclosed
WO-2009071553-A1 NEW THERAPEUTIC USES OF DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE PALUMED S.A. (FR) 2009-06-11 WO disclosed
WO-2007144487-A2 DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES SANOFI-AVENTIS (FR) 2007-12-21 WO disclosed
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 US disclosed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US disclosed
WO-2003070244-A1 ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES ABBOTT LABORATORIES (US) 2003-08-28 WO disclosed
EP-0876346-B1 ANTIMALARIAL QUINOLIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2001-07-25 EP disclosed
US-5948791-A Quinoline derivatives for treating malaria HOFFMANN-LA ROCHE INC. (US) 1999-09-07 US disclosed
EP-0876346-A1 ANTIMALARIAL QUINOLIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1998-11-11 EP disclosed
WO-1997018193-A1 ANTIMALARIAL QUINOLIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1997-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor MCHR1, MCHR2, MC1R KMT5B 1214/4885KMT5C 1285/4885NSD2 2914/4885
US-20120122923-A1 DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES DUOX2, DUOX1, CYP11B2 KMT5B 4550/4885KMT5C 4536/4885NSD2 4357/4885
US-20110045100-A1 Antimalarial Quinolines and Methods of Use Thereof NQO2, QTRT1, QTRT2 KMT5B 999/4885KMT5C 906/4885NSD2 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.